Archived News Headlines
We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.
Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
The Leukemia & Lymphoma Society to Fund Research Focused on Long-Term and Late Effects of Cancer Treatment
(CNBC.com) Sept 14, 2009 - The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments.
read article 
NCCN Holds Oncology Research Best Practices Conference
(MarketWatch.com) Sept 14, 2009 - Significant strides in the prevention, detection, and treatment of cancer have been made possible through clinical
trials, however regulatory and ethical issues can pose challenges to clinical investigators.
read article
Report Slams Uneven Coverage of Cancer Drugs
(Globe and Mail, Canada) Sept 14, 2009 - The gross and ever-widening disparities in the coverage of cancer drugs is causing widespread financial hardship and undermining medicare, the Canadian Cancer Society warns in a stinging new report.
read article
Lilly Plans to Cut $1B by 2011
(Indianapolis Star) Sept 14, 2009 - Facing huge financial pressures, Eli Lilly and Co. said today that it plans to cut employee headcount worldwide by 5,500, or about 13 percent, by the end of 2011, as part of a move to slash $1 billion in costs.
read article
Study: New Drug Fights Flu As Well As Tamiflu Does
(Boston Globe) Sept 13, 2009 - Researchers delivered a double dose of good news Sunday in the fight against flu: successful tests of what could become the first new flu medicine in a decade, and the strongest evidence yet that such drugs save lives, not just shorten illness.
read article (free registration required)
Theravance, Astellas Get U.S. Approval for Antibiotic
(Bloomberg) Sept 12, 2009 - Theravance Inc. and Astellas Pharma Inc. said they received U.S. approval to market a new antibiotic for hard-to-treat skin infections such as methicillin-resistant Staphylococcus aureus, or MRSA, which kills almost 19,000 Americans a year.
read article
Merck Drug Case Ends in a Mistrial
(NJ.com) Sept 11, 2009 - A federal judge declared a mistrial yesterday in the first trial over whether Merck's former blockbuster osteoporosis drug, Fosamax, causes painful jaw bone destruction.
read article
Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis
(StreetInsider.com) Sept 13, 2009 - Amgen Inc. today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis.
read article
Regeneron, Sanofi Drug Fails Against Pancreatic Cancer
(Reuters) Sept 11, 2009 - Sanofi-Aventis and Regeneron Pharmaceuticals on Friday said they had halted the trial of a drug for treatment of pancreatic cancer because it was not effective, but would continue studies of the drug to treat other cancers.
read article
Ariad Says Independent Experts Positive on Cancer Drug
(Reuters) Sept 14, 2009 - Ariad Pharmaceuticals Inc said an independent committee of experts recommended that a late-stage trial of the company's experimental cancer treatment may continue, sending its shares up 12 percent.
read article
Breast Cancer Gene Testing for Roche’s Herceptin Often Lacking
(Bloomberg) Sept 14, 2009 - A genetic test used to determine if breast cancer patients should receive Roche Holding AG’s Herceptin is often not given to patients, according to a report.
read article
Ghostwriting Is Called Rife in Medical Journals
(New York Times) Sept 10, 2009 - Six of the top medical journals published a significant number of articles in 2008 that were written by ghostwriters financed by drug companies, according to a study released Thursday by editors of The Journal of the American Medical Association.
read article (free registration required)
Sanofi Can Pursue Court Bid to Block Generic Eloxatin
(Bloomberg) Sept 10, 2009 - Sanofi-Aventis SA, France’s biggest drugmaker, won an appeals court ruling that revives its efforts to block copies of the colon cancer drug Eloxatin in the U.S. until 2013.
read article
Treating Childhood Leukemia With Fewer Side Effects
(U.S. News & World Report) Sept 10, 2009 - Adding the corticosteroid dexamethasone to the treatment regimen of children with acute lymphoblastic leukemia improves survival rates and reduces the incidence of the cancer recurring, a new Dutch study shows.
read article
Millennium Starts Phase II Trial of Cancer Drug
(Boston Globe) Sept 11, 2009 - Takeda Pharmaceutical Co. Ltd. and its Cambridge subsidiary Millennium: The Takeda Oncology Company announced the start of the Phase II portion of a Phase I/II clinical trial of a potential treatment for advanced prostate cancer.
read article (free registration required)
Sanofi Can Pursue Court Bid to Block Generic Eloxatin
(Bloomberg) Sept 10, 2009 - Sanofi-Aventis SA, France’s biggest drugmaker, won an appeals court ruling that revives its efforts to block copies of the colon cancer drug Eloxatin in the U.S. until 2013.
read article
Treating Childhood Leukemia With Fewer Side Effects
(BusinessWeek.com) Sept 10, 2009 - Adding the corticosteroid dexamethasone to the treatment regimen of children with acute lymphoblastic leukemia improves survival rates and reduces the incidence of the cancer recurring, a new Dutch study shows.
read article
Millennium Starts Phase II Trial of Cancer Drug
(Boston Globe) Sept 11, 2009 - Takeda Pharmaceutical Co. Ltd. and its Cambridge subsidiary Millennium: The Takeda Oncology Company announced the start of the Phase II portion of a Phase I/II clinical trial of a potential treatment for advanced prostate cancer.
read article (free registration required)
Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
(CNNMoney.com) Sept 10, 2009 - Amgen today announced that new data will be presented on the burden of osteoporosis, current osteoporosis treatment challenges and Prolia(TM) (denosumab) at the 2009 American Society for Bone and Mineral Research (ASBMR) annual meeting in Denver from Sept. 11-15, 2009.
read article
Novel “On-Off Switch” Mechanism Stops Cancer in Its Tracks
(Yale University) Sept 11, 2009 - A tiny bit of genetic material with no previously known function may hold the key to stopping the spread of cancer, researchers at Yale School of Medicine and Sichuan University in Chengdu, China report in two papers in the September 7-11 issue of Proceedings of the National Academy of Sciences.
read press release
Replication at DNA Damage Sites Highlights Fanconi Anemia and Breast Cancer Proteins
(M. D. Anderson) Sept 10, 2009 - While Fanconi anemia (FA) is a rare and dangerous disease, new laboratory research at The University of Texas M. D. Anderson Cancer Center shows it may lead researchers toward clues in more common diseases, including highly hereditary types of breast cancer.
read press release
New Stem Cell Identification Technology Could Cure Breast Cancer
(Reuters) Sept 11, 2009 – GENova Biotherapeutics, Inc., released important information about its innovative method for destroying breast cancer cells, using stem cell technology.
read article
Nearly Any Lifetime Smoking Ups Breast Cancer Risk
(Reuters) Sept 10, 2009 - Women taking the next puff of a cigarette might consider this: smoking 100 or more cigarettes may substantially increase their odds of developing breast cancer, researchers report.
read article
Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain
(MarketWatch.com) Sept 11, 2009 - New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain.
read article
Biotech Stock Mailbag: Genta Takes Another Stab
(TheStreet.com) Sept 11, 2009 - The Biotech Stock Mailbag is open for business. Let's kicks things off with an email about Genta.
read article